These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 8633252)

  • 1. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile.
    Rougier P; Bugat R
    Semin Oncol; 1996 Feb; 23(1 Suppl 3):34-41. PubMed ID: 8633252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
    Rougier P; Bugat R; Douillard JY; Culine S; Suc E; Brunet P; Becouarn Y; Ychou M; Marty M; Extra JM; Bonneterre J; Adenis A; Seitz JF; Ganem G; Namer M; Conroy T; Negrier S; Merrouche Y; Burki F; Mousseau M; Herait P; Mahjoubi M
    J Clin Oncol; 1997 Jan; 15(1):251-60. PubMed ID: 8996150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CPT-11: an original spectrum of clinical activity.
    Rothenberg ML
    Semin Oncol; 1996 Feb; 23(1 Suppl 3):21-6. PubMed ID: 8633249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topoisomerase I inhibitors in the treatment of colorectal cancer.
    Rothenberg ML; Blanke CD
    Semin Oncol; 1999 Dec; 26(6):632-9. PubMed ID: 10606256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective comparison of single-agent chemotherapy with weekly 5-fluorouracil or weekly irinotecan in previously treated patients with metastatic colorectal cancer.
    Lavrenkov K; Man S; Mermershtain W; Cohen Y
    J Chemother; 2002 Feb; 14(1):84-7. PubMed ID: 11892905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and toxicity of irinotecan in patients with colorectal cancer.
    Rothenberg ML
    Semin Oncol; 1998 Oct; 25(5 Suppl 11):39-46. PubMed ID: 9786315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer.
    Shimada Y; Rougier P; Pitot H
    Eur J Cancer; 1996; 32A Suppl 3():S13-7. PubMed ID: 8943660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. US pivotal studies of irinotecan in colorectal carcinoma.
    Pitot HC
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):48-53. PubMed ID: 9726091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
    Freyer G; Rougier P; Bugat R; Droz JP; Marty M; Bleiberg H; Mignard D; Awad L; Herait P; Culine S; Trillet-Lenoir V
    Br J Cancer; 2000 Aug; 83(4):431-7. PubMed ID: 10945486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CPT-11 (irinotecan) in the treatment of colorectal cancer.
    Armand JP; Ducreux M; Mahjoubi M; Abigerges D; Bugat R; Chabot G; Herait P; de Forni M; Rougier P
    Eur J Cancer; 1995; 31A(7-8):1283-7. PubMed ID: 7577037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CPT-11: the European clinical development.
    Terret C; Couteau C; Armand JP
    J Infus Chemother; 1996; 6(3):152-7. PubMed ID: 9229329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.
    Wiseman LR; Markham A
    Drugs; 1996 Oct; 52(4):606-23. PubMed ID: 8891470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irinotecan hydrochloride: drug profile and nursing implications of a topoisomerase I inhibitor in patients with advanced colorectal cancer.
    Berg D
    Oncol Nurs Forum; 1998 Apr; 25(3):535-43. PubMed ID: 9568608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer.
    Fuchs CS; Moore MR; Harker G; Villa L; Rinaldi D; Hecht JR
    J Clin Oncol; 2003 Mar; 21(5):807-14. PubMed ID: 12610178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer.
    Benavides M; García-Alfonso P; Cobo M; Muñoz-Martín A; Gil-Calle S; Carabantes F; Villar E; Graupera J; Balcells M; Pérez-Manga G
    Med Oncol; 2004; 21(3):255-62. PubMed ID: 15456953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Irinotecan: various administration schedules, study of drug combinations, phase I experience].
    Boige V; Raymond E; Armand JP
    Bull Cancer; 1998 Dec; Spec No():26-32. PubMed ID: 9932081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CPT-11: clinical experience in phase I studies.
    Armand JP
    Semin Oncol; 1996 Feb; 23(1 Suppl 3):27-33. PubMed ID: 8633250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [[Irinotecan--experience with second-line treatment in advanced colorectal cancer] ].
    Kristó K; Izsó J; Balatoni G; Lohinszky J; Farczádi E; Szántó J; Kofi AP; Pintér T
    Orv Hetil; 2000 Aug; 141(33):1817-20. PubMed ID: 10979311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.
    Saliba F; Hagipantelli R; Misset JL; Bastian G; Vassal G; Bonnay M; Herait P; Cote C; Mahjoubi M; Mignard D; Cvitkovic E
    J Clin Oncol; 1998 Aug; 16(8):2745-51. PubMed ID: 9704727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials].
    Van Cutsem E; Peeters M
    Bull Cancer; 1998 Dec; Spec No():33-7. PubMed ID: 9932082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.